Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 312

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 312
---
           Total    Preferred Stock  Preferred Stock  Common stock  Additional    Accumulated  Stockholders’   Shares   Amount  Shares   Amount  Shares   Amount  Paid in Capital  Stock Payable  Deficit  Equity Balance as of December 31, 2022   141.397  $1   -  $-   1,811  $-  $89,068,332  $6,073  $(81,869,902) $7,204,504 Common stock issued for cash, net of funding costs  -   -   -   -   3,221   1   6,483,392   -   -   6,483,393 Common stock issued for warrant exercise  -   -   -   -   905   -   1,014,859   -   -   1,014,859 Warrants issued for cash, net of funding costs  -   -   -   -   -   -   20,053   -   -   20,053 Fair value of vested stock options  -   -   -   -   -   -   996,430   -   -   996,430 Stock payable towards preference dividend  -   -   -   -   -   -   840   (840)  -   - Net loss  -   -   -   -   -   -   -   -   (10,060,250)  (10,060,250)Balance as of December 31, 2023   141.397  $1   -  $-   5,937  $1  $97,583,906  $5,233  $(91,930,152) $5,658,989 

Year Ended December 31, 2024  Series A Convertible  Series B Convertible             Total    Preferred Stock  Preferred Stock  Common stock  Additional    Accumulated